5xFAD Transgenic Mouse Model

5xFAD Transgenic Mouse Model

Overview

The 5xFAD mouse is one of the most widely used transgenic mouse models of Alzheimer's disease. Developed by Oakley et al. in 2006[@oakley2006], it co-expresses five familial AD mutations in human [APP](/genes/app) and [PSEN1](/genes/psen1) genes, producing rapid and robust amyloid-beta pathology with plaque onset as early as 2 months of age. This makes it one of the fastest-acting amyloid models available.

The model is particularly valuable for studying amyloid-driven neurodegeneration, neuroinflammation, and synaptic dysfunction. While it lacks robust neurofibrillary tangle formation (unlike the [3xTG-AD model](/models/3xtg-ad-mouse)), its rapid phenotype enables efficient therapeutic testing[@hong2016].

Model Generation and Genetic Background

Construct Design

The 5xFAD transgenic construct expresses human APP with three Swedish/Florida/London mutations combined with two PSEN1 mutations[@oakley2006]:

| Gene | Mutation | Position | Effect |
|------|----------|----------|--------|
| [APP](/genes/app) | Swedish (K670N/M671L) | 670/671 | Enhanced β-secretase cleavage, 3-4× more Aβ |
| [APP](/genes/app) | Florida (I716V) | 716 | Increased Aβ production |
| [APP](/genes/app) | London (V717I) | 717 | Altered γ-secretase processing |
| [PSEN1](/genes/psen1) | M146L | 146 | Increased Aβ42/Aβ40 ratio |
| [PSEN1](/genes/psen1) | L286V | 286 | Increased Aβ42/Aβ40 ratio |

5xFAD Transgenic Mouse Model

Overview

The 5xFAD mouse is one of the most widely used transgenic mouse models of Alzheimer's disease. Developed by Oakley et al. in 2006[@oakley2006], it co-expresses five familial AD mutations in human [APP](/genes/app) and [PSEN1](/genes/psen1) genes, producing rapid and robust amyloid-beta pathology with plaque onset as early as 2 months of age. This makes it one of the fastest-acting amyloid models available.

The model is particularly valuable for studying amyloid-driven neurodegeneration, neuroinflammation, and synaptic dysfunction. While it lacks robust neurofibrillary tangle formation (unlike the [3xTG-AD model](/models/3xtg-ad-mouse)), its rapid phenotype enables efficient therapeutic testing[@hong2016].

Model Generation and Genetic Background

Construct Design

The 5xFAD transgenic construct expresses human APP with three Swedish/Florida/London mutations combined with two PSEN1 mutations[@oakley2006]:

| Gene | Mutation | Position | Effect |
|------|----------|----------|--------|
| [APP](/genes/app) | Swedish (K670N/M671L) | 670/671 | Enhanced β-secretase cleavage, 3-4× more Aβ |
| [APP](/genes/app) | Florida (I716V) | 716 | Increased Aβ production |
| [APP](/genes/app) | London (V717I) | 717 | Altered γ-secretase processing |
| [PSEN1](/genes/psen1) | M146L | 146 | Increased Aβ42/Aβ40 ratio |
| [PSEN1](/genes/psen1) | L286V | 286 | Increased Aβ42/Aβ40 ratio |

The APP transgene is driven by the mouse Thy1 promoter, providing neuron-specific expression. The combination of five FAD mutations dramatically shifts APP processing toward Aβ42 production, driving rapid pathology.

Breeding and Maintenance

The 5xFAD line is maintained on a C57BL/6J background. Mice are typically heterozygous for the transgene, as homozygous mice show more severe phenotypes and reduced viability. The model is available from The Jackson Laboratory (strain #006554).

Neuropathological Features

Amyloid Plaque Deposition

The 5xFAD model demonstrates exceptionally rapid amyloid plaque formation[@oakley2006]:

• Pre-plaque (1-2 months): Subtle diffuse Aβ deposits detectable by immunohistochemistry
• Plaque onset (2-3 months): Compact, thioflavin-S positive plaques appear in cortical regions (subiculum first)
• Established (4-6 months): Extensive plaque burden throughout cortex, hippocampus, and subiculum
• Advanced (6-12 months): Heavy plaque load with associated neuronal loss

Regional Distribution

Plaque distribution follows a characteristic pattern:

Neuronal Loss and Synaptic Pathology

5xFAD mice exhibit progressive neuronal loss[@hong2016]:

• Cortical neurons: Significant loss in layer 5 by 6 months
• Hippocampal CA1: Progressive degeneration of pyramidal neurons
• Subiculum: Early and severe neuronal dropout
• Synaptic markers: Reduced synaptophysin and PSD-95 expression by 4 months

Gliosis and Neuroinflammation

Astrocytic and microglial activation accompanies amyloid deposition[@boza2019]:

• Astrocytes: GFAP-positive astrocytes surround plaques; A1 (neurotoxic) phenotype predominates near plaques[@fan2020]
• Microglia: Iba1-positive cells show increased activation; disease-associated microglia (DAM) phenotype with TREM2 upregulation
• Complement: C1q and C3 deposition at plaque sites — drives synaptic pruning deficits[@shi2022]
• Cytokines: Elevated IL-1β, TNF-α in brain tissue[@demars2021]

Tau Pathology

The 5xFAD model shows limited endogenous tau pathology[@jawhar2011]:

• Phosphorylated tau: Accumulation of endogenous mouse tau, particularly at Ser202/Thr205 (AT8 epitope), starting around 6 months
• True NFTs: Minimal — unlike the [3xTG-AD model](/models/3xtg-ad-mouse), few neurofibrillary tangles form

Behavioral Phenotype

Cognitive Deficits

Memory impairment in 5xFAD mice follows a progressive course[@crews2010]:

• Morris water maze: Impaired spatial learning by 4-6 months; reduced time in target quadrant, increased path length[@mclean2017]
• Contextual fear conditioning: Reduced freezing in context testing by 4-6 months
• Y-maze: Reduced spontaneous alternation by 5-7 months; working memory deficits
• Novel object recognition: Impaired discrimination index by 5 months[@mclean2017]

Motor Function

Motor deficits appear later than cognitive changes:

• Rotarod: Impaired performance at 8-10 months
• Grid walk: Foot fault errors increase with age
• Gait analysis: Altered stride length and paw pressure

Molecular Mechanisms

Early Network Dysfunction

5xFAD mice exhibit early hippocampal network dysfunction before significant amyloid plaque deposition[@zhao2017]. Soluble Aβ oligomers — not plaques — drive early cognitive impairment.

Key electrophysiological changes[@kort2020]:

• Reduced long-term potentiation (LTP) in hippocampal CA1 as early as 4 months
• Impaired synaptic plasticity and NMDA receptor dysfunction
• Disrupted gamma oscillations (30-100 Hz) and altered theta-gamma coupling
• Increased inhibitory interneuron activity

Mitochondrial Dysfunction

5xFAD neurons show significant mitochondrial abnormalities[@song2019]:

• Reduced complex IV activity
• Decreased ATP production
• Increased reactive oxygen species (ROS)
• Elevated mitochondrial DNA damage

Synaptic Pruning Deficits

5xFAD mice exhibit excessive microglial phagocytosis of synapses via complement-mediated pathways[@shi2022]:

• Elevated complement C1q targeting synapses
• Decreased PSD-95 and synaptophysin levels
• Correlation between synaptic loss and cognitive decline

CSF Biomarker Correlation

5xFAD mice parallel human AD biomarker trajectories[@cruchaga2020]:

• CSF Aβ42 decreases as plaques form (reflecting plaque sink effect)
• CSF total tau increases with age
• Phosphorylated tau (p-tau181) correlates with hippocampal atrophy

Neurovascular Dysfunction

5xFAD mice show impaired neurovascular function[@hu2018]:

• Reduced cerebral blood flow
• Impaired blood-brain barrier integrity
• Decreased vessel density

Research Applications

Therapeutic Testing

The 5xFAD model is extensively used for drug development:

• Anti-Aβ antibodies: Donanemab, lecanemab validation studies
• BACE1 inhibitors: Reduce Aβ production
• γ-secretase modulators: Shift Aβ profile toward shorter species
• TREM2-targeting approaches: Microglial modulation[@wang2022]
• Oligomer-specific agents: Targeted small molecules[@schelle2019]

Biomarker Development

The model enables validation of biomarkers:

• CSF biomarkers: Aβ42, tau, p-tau181 correlation with brain pathology
• Plasma biomarkers: GFAP, neurofilament light (NFL)
• Imaging biomarkers: PET ligand binding correlation
• Neurophysiological markers: EEG, evoked potentials[@kort2020]

Mechanism Studies

Researchers use 5xFAD to investigate:

• Amyloid toxicity mechanisms (soluble oligomers vs. plaques)
• Synaptic dysfunction pathways
• Neuroinflammation progression
• Neuronal death cascades

Experimental Considerations

Key Timepoints

| Age | Stage | Phenotype |
|-----|-------|-----------|
| 1-2 months | Pre-plaque | Baseline behavior, subtle Aβ |
| 2-4 months | Early plaque | Subtle cognitive deficits |
| 4-6 months | Established | Clear cognitive deficits, synaptic loss |
| 6-9 months | Advanced | Severe pathology, gliosis |
| 9-12 months | Late | Maximal pathology, neuronal loss |

Sex Differences

• Females: Earlier plaque onset, potentially more severe pathology
• Males: Slightly delayed phenotype
• Recommendation: Match sex for experimental groups

Comparison with Other AD Models

| Model | Transgenes | Plaque Onset | Tangles | Cognitive Deficit |
|-------|------------|-------------|---------|-------------------|
| 5xFAD | APP×3 + PSEN1×2 | 2 months | Minimal | 4-6 months |
| 3xTG-AD | APP + TAU + PSEN1 | 6 months | 12 months | 6-10 months |
| APP/PS1 | APP + PSEN1 | 6-9 months | No | 8-12 months |
| Tg2576 | APP Swedish | 9-12 months | No | 12-15 months |

Strengths

• Rapid phenotype: Plaques appear in 2 months vs. 6-12 months in other models
• Robust and reproducible: Consistent across mice and facilities
• Well-characterized: Extensive published literature
• Cognitive deficits: Clear learning and memory impairments
• Microglia studies: Excellent for studying neuroinflammation[@boza2019]

Limitations

• No tau tangles: Lacks neurofibrillary pathology
• Artificial genetics: Five mutations rarely co-occur naturally
• Aggressive phenotype: More severe than sporadic AD
• Male variability: Some phenotypic variability by sex

Key Publications

Cross-Links

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [3xTG-AD Mouse Model](/models/3xtg-ad-mouse)
• [APP Gene](/genes/app)
• [PSEN1 Gene](/genes/psen1)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
• [TREM2 Gene](/genes/trem2)
• [MPTP Mouse Model (PD reference)](/models/mptp-mouse-model-parkinsons)